Tsubota Laboratory: Announcements of individual stocks relating to relocation of headquarters.
Tsubota Laboratory: Financial results announcement for the first quarter of FY2025 (Japanese standard) (unconsolidated)
Tsubota Laboratory: Announcements of individual stocks regarding the publication of the research paper "Establishment of in vitro choroidal complex for vascular response screening"
Tsubota Laboratory: A report on the preliminary clinical trial results for TLG-005 targeting depression.
Tsubota Laboratory: Announcement of preliminary results of specific clinical study of TLG-005 targeting Parkinson's disease.
Tsubota Laboratory: Our representative, Kazuo Pingda, has been appointed as a visiting professor of ophthalmology at Wenzhou Medical University.
Tsubota Laboratory: A Japanese company has opened an office for the first time in Eye Valley, Wenzhou, Zhejiang Province.
Tsubota Laboratory: Regarding matters related to dominant shareholders.
Tsubota Laboratory: Report on Corporate Governance, June 28th, 2024.
Tsubota Laboratory: Internal Control Report - 12th Term (2023/04/01 - 2024/03/31)
Tsubota Laboratory: Confirmatory letter.
Tsubota Laboratory: Securities Report - 12th Period (April 1, 2023 - March 31, 2024)
Tsubota Laboratory: About the license agreement in the American continent related to TLG-001.
Tsubota Laboratory: Announcements of individual stocks: Change in Planned Timing for Use of Funds Raised through Listing.
Tsubota Laboratory: Matters related to business plans and growth potential.
Tsubota Laboratory: Notice of Regular Shareholders' Meeting Convened in 2024 and Shareholders' Meeting Materials.
Tsubota Laboratory: Completion of the TLG-005 (Parkinson's disease) project with Sumitomo Pharma Co., Ltd. and future research policies
Tsubota Laboratory: Presented 16 abstracts at the 6th Annual Meeting of the Japanese Myopia Society
Tsubota Laboratory: Financial results presentation materials for the fiscal year ending March 2024
Tsubota Laboratory: Summary of financial results for the fiscal year ending March 31, 2024 [Japanese GAAP] (unconsolidated)
No Data